ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb and Merck have agreed to end a pact to develop the diabetes drug Pargluva following an October request by FDA for additional information on the drug's cardiovascular profile. Under the agreement, all rights to the drug revert to BMS, which says it is considering a range of options, including conducting additional studies or ending development of the drug. BMS told analysts last month that a delay in approval for Pargluva is among the factors that will defer growth at the company until 2007 (C&EN, Dec. 19, 2005, page 12).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter